Obiltoxaximab

Identification

Name
Obiltoxaximab
Accession Number
DB05336
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.

Protein chemical formula
Not Available
Protein average weight
148000.0 Da
Sequences
Not Available
Synonyms
Not Available
External IDs
ETI-204
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AnthimSolution100 mg/1mLIntravenousElusys Therapeutics, Inc.2016-03-18Not applicableUs
Categories
UNII
29Z5DNL48C
CAS number
1351337-07-9

Pharmacology

Indication

Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

ETI-204 is an affinity-enhanced, de-immunized antibody, which means that its ability to bind to its target pathogen has been strengthened and that elements that might cause an immune response have been removed. ETI-204 targets and binds to Protective Antigen, which prevents the anthrax toxins from binding to and entering the cells in the body, thereby preventing death.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Obiltoxaximab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Obiltoxaximab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Obiltoxaximab.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Obiltoxaximab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Obiltoxaximab.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Obiltoxaximab.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Obiltoxaximab.
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Obiltoxaximab.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Obiltoxaximab.
BevacizumabThe risk or severity of adverse effects can be increased when Bevacizumab is combined with Obiltoxaximab.
Food Interactions
Not Available

References

General References
  1. Mohamed N, Clagett M, Li J, Jones S, Pincus S, D'Alia G, Nardone L, Babin M, Spitalny G, Casey L: A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun. 2005 Feb;73(2):795-802. [PubMed:15664918]
External Links
PubChem Substance
347910089
Wikipedia
Obiltoxaximab
FDA label
Download (315 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableInhaled anthrax caused by Bacillus anthracis4
1CompletedTreatmentAnthrax1
1CompletedTreatmentBacillus Anthracis (Anthrax)1
1CompletedTreatmentHealthy Volunteers1
4Not Yet RecruitingTreatmentAnthrax / Bacterial Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionIntravenous100 mg/1mL
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on November 18, 2007 11:23 / Updated on October 01, 2018 14:00